Convergent evolution of resistance pathways during early stage breast cancer treatment with combination cell cycle (CDK) and endocrine inhibitors
J. I. Griffiths, J. Chen, P. A. Cosgrove, A. O'Dea, P. Sharma, C. Ma, M. Trivedi, K. Kalinsky, K. B. Wisinski, R. O'Regan, , I. Makhoul, L. M. Spring, A. Bardia, F. R. Adler, A. L. Cohen, , A. Bild
This study examines how breast cancer tumors evolve during early stage treatment with combination CDK and endocrine inhibitors, finding convergent resistance pathways and increased subclonal diversity with combination therapy.
bioRxiv · Jan 19, 2021 · PreprintCancer Biology